Blockchain Registration Transaction Record

Sigyn Therapeutics Unveils CardioDialysis™ for Heart Disease, Eyes Merger Strategy

Sigyn Therapeutics CEO Jim Joyce updates on CardioDialysis™ for heart disease and sepsis treatment, plus merger plans to uplist from OTCQB. Learn about innovative dialysis-like therapies.

This news matters because it addresses two of healthcare's most pressing challenges: cardiovascular disease and sepsis, which together account for millions of deaths globally annually. Sigyn's CardioDialysis™ represents a potential paradigm shift by leveraging existing dialysis infrastructure to treat heart disease more effectively than current drugs, potentially reducing heart attacks and strokes on a large scale. For patients, this could mean more accessible, non-pharmaceutical interventions for life-threatening conditions. The company's financial strategies, including a potential merger, highlight the real-world hurdles innovative biotech firms face in securing funding for breakthrough therapies, which directly impacts how quickly such treatments can reach the market. Investors and the medical community should watch closely, as success here could catalyze similar approaches in therapeutic device development.